Prospective, multicenter, randomized and open label study evaluating the benefit on renal function at 12 months post-transplantation, with an immunosuppression without calcineurin inhibitor at 3 months and combining mycophenolate sodium-Everolimus versus an immunosuppression combining Everolimus-Tacrolimus, in de novo renal transplant patients.

Inclusion Criteria:

• Patients receiving a first kidney transplant from a cadaveric or living donor

Exclusion Criteria:

• Double transplant
• Patient who has been treated with an immunosuppressive drug or study drug during the four weeks before administration of the first dose of Everolimus